|
|
Article: Circassia Announces Acquisition of Organ Transplant Anti-Rejection Technology.
- Article from:
- PR Newswire
- Article date:
- July 12, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Expands Circassia's Pipeline of Immune Control Products
Complements Circassia's Anti-Allergy Technology
OXFORD, England, July 12 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the acquisition of a novel anti-rejection technology for use in organ transplantation. Circassia acquired the proprietary technology, known as ToleroTrans, from The University of Birmingham in the UK for an undisclosed upfront sum, plus future milestone payments and royalties on product sales. Scientifically, the ToleroTrans approach mirrors that of Circassia's existing anti-allergy technology, ...